ENHERTU Demonstrated Statistically Significant and Clinically Meaningful OS Improvement in Patients with HER2+ve Metastatic Gastric Cancer at Interim Analysis of DESTINYGastric04 Ph 3 Trial
“ENHERTU is the first HER2 directed medicine to demonstrate an improvement in overall survival in a randomized phase 3 trial in the second-line metastatic setting of patients with HER2 positive gastric cancer, 2 reinforcing previous findings seen in our other earlier phase gastric cancer trials,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “With these DESTINY-Gastric04 results, we will work with global regulatory authorities to seek approval in regions where ENHERTU is not currently indicated as a second line option as well as work to secure full approval in regions where ENHERTU is conditionally approved.”
Share:
More News
“We would like to thank Novartis for this groundbreaking research collaboration which enabled us to launch our activities in the field of targeted radiopharmaceuticals. We developed know-how, attracted a strong team of experts and evolved our Radio-DARPin platform. As it stands today, we are not planning to integrate these programs
“Adding dordaviprone to our oncology R&D pipeline will further diversify our portfolio with a medicine that addresses a significant unmet need with no other FDA-approved therapies and limited treatment options for this patient population. If approved, dordaviprone has the potential to rapidly become a standard of care for a rare
“We are thrilled to share that the first trial site has been initiated and activation of additional clinical sites continues,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. “Considering the strength and durability of the clinical responses in our VERSATILE-002 study, we are pleased to get
“The HARMONi-2 study demonstrated that in the intent-to-treat population, ivonescimab monotherapy significantly extended progression-free survival (PFS) compared to pembrolizumab monotherapy, reducing the risk of disease progression by 49% (PFS HR 0.51, P<0.0001). Subgroup analyses revealed that regardless of patients’ age, gender, ECOG performance status, PD-L1 expression, histological type, or the
